Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies.
To evaluate the efficacy of cladribine and cytarabine in children with relapsed or refractory myeloid malignancies, we administered cytarabine (200 mg/m2 per day) by continuous subcutaneous infusion and cladribine (8.9 mg/m2 per day) by continuous intravenous infusion concomitantly for 5 days to nine patients younger than 21 years. After one course, five patients had no response, two patients had partial responses, one had stable disease, and one had progressive disease. Two patients received a second course: one patient had stable disease after one course and progressive disease after the second; another patient had a partial response after one course and no response after the second. Despite the efficacy of the cladribine and cytarabine regimen in treating newly diagnosed acute myeloid leukemia (AML) in a previously reported study, the combination was not effective for relapsed or refractory childhood AML.
Rubnitz
Jeffrey E
JE
Department of Hematology-Oncology, St. Jude Children's Research Hospital, Mail Stop 260, 332 N. Lauderdale Street, Memphis, TN 38105-2794, USA. jeffrey.rubnitz@stjude.org
Razzouk
Bassem I
BI
Srivastava
Deo Kumar
DK
Pui
Ching-Hon
CH
Ribeiro
Raul C
RC
Santana
Victor M
VM
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002675:Child, Preschool; D017338:Cladribine / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D008297:Male; D012008:Recurrence; D016896:Treatment Outcome
D003561:Cytarabine; D017338:Cladribine